Waltham, MA, United States of America

Mei Su

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.7

ph-index = 1


Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mei Su: Innovator in Cancer Treatment

Introduction

Mei Su is a prominent inventor based in Waltham, MA (US), known for her significant contributions to the field of cancer treatment. With a total of 3 patents, she has developed innovative compounds that aim to improve therapeutic options for patients suffering from various forms of cancer.

Latest Patents

Mei Su's latest patents include groundbreaking inventions such as 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl)-3H-imidazo[4,5-B] pyridin-5-amine derivatives. These compounds are designed for the treatment of myeloproliferative disorders and cancer, providing new pharmaceutical compositions and methods of use. Another notable patent involves 4-(3-aminopyrazole) pyrimidine derivatives, which serve as tyrosine kinase inhibitors in cancer treatment. These novel compounds also offer promising therapeutic benefits for cancer patients.

Career Highlights

Mei Su is currently employed at AstraZeneca AB, where she continues to advance her research and development efforts in oncology. Her work has been instrumental in creating effective treatments that target cancer at the molecular level.

Collaborations

Throughout her career, Mei has collaborated with esteemed colleagues such as Stephanos Ioannidis and Tao Wang. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of effective cancer therapies.

Conclusion

Mei Su's contributions to cancer treatment through her innovative patents and collaborations highlight her role as a leading inventor in the pharmaceutical industry. Her work continues to pave the way for advancements in cancer therapies, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…